040-66808040
Updates

 2021-22


Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 27th May, 2021:

(a)    The Audited financial results for the quarter and Year ended 31st March, 2021 along with the Auditor Report thereon  have been adopted by the Board.

Intimation of Board meeting

We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 27th May, 2021 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and year ended 31st March 2021.

2. Any other matter with the permission of the Chair.

Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 29th December 2020 and shall re-open 48 hours after the declaration of results

 2020-21


Outcome of the Board meeting held on 6th April, 2021

we herewith intimate to the Exchange that

1.Pursuant to our intimation letters dated 1st February, 2020 and 5th February, 2020, the approval of shareholders at the Extra Ordinary General meeting, in-principal approval received form the Stock exchanges and upon   receipt of the necessary application money, the Board of directors at their meeting held on 5th February, 2020 had allotted 3560000 warrants convertible into equity shares to M/s. Ipca Laboratories Limited, part of the Promoter Group of the Company..

2.Pursuant to the exercise of conversion option by Ipca Laboratories Ltd. and upon receipt of the application money the Board of directors of the Company at their meeting held on 20-05-2020 have converted 16,20,000 warrants into 16,20,000 equity shares, which was intimated to stock exchange on 20th May, 2020.

3.Pursuant to the exercise of further conversion option by Ipca Laboratories Ltd. and upon receipt of the balance application money, the Board of directors of the Company at their meeting held today  i.e on 6th April, 2021 have converted 19,40,000 warrants and allotted 19,40,000 (Nineteen Lakhs Forty Thousand ) Equity shares of Rs.10/- each  of the Company at a price of Rs. 86/- per Equity Share, including premium of Rs. 76/- per share to M/s Ipca Laboratories Limited, the entity forming part of the promoter group. The Equity shares now allotted on conversion of warrants issued shall rank pari passu with the existing equity shares of the Company in all respects.

The paid up equity capital of the company with the aforesaid allotment has increased from 19620586 equity of Rs. 10/- each to 21560586 Equity shares of Rs.10/- each aggregating to Rs.21,56,05,860

Outcome of the Board meeting held on 30th January, 2021

We wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 5th November ,2020 :

(a) The unadited financial results for the quarter and Half Year ended 30th September, 2020 along with the Auditor’s Limited Review Report thereon (Enclosed herewith) have been adopted by the Board.

Intimation of Board meeting on 30th January, 2021

we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Saturday, 30th January, 2021 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 31st December 2020.

2. Any other matter with the permission of the Chair.

Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 29th December 2020 and shall re-open 48 hours after the declaration of results

Outcome of Board Meeting dated 5th November ,2020

we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 5th November ,2020 :

(a)    The unadited financial results for the quarter and Half Year ended 30th September, 2020 along with the Auditor’s Limited Review Report thereon (Enclosed herewith) have been adopted by the Board.

(b)   The  Board of Directors at its meeting held on 5th November ,2020 have considered and approved Re-Appointment of Mr. Raj Kamal Prasad Verma as Independent Director for a further  Period of 5years (Second Term) with effect from 13th February, 2021

Intimation of Board meeting on 5th November, 2020

we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 5th November, 2020 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and half year ended 30th September 2020.

2. Any other matter with the permission of the Chair.

Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 1st October 2020 and shall re-open 48 hours after the declaration of results.

Outcome of Board meeting held on 7th August, 2020 

we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 7th August,2020 :

(a)    The Unaudited financial results for the quarter ended 30th June, 2020 along with the Limited review Report thereon (Enclosed herewith) have been adopted by the Board.

(b)    The Board’s Report and annexures has been approved for the 28th Annual General Meeting.

Intimation of Board Meeting

We herewith intimate that the meeting of Board of Directors of the Company is scheduled to be held on Friday, 7th August 2020 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 30th June 2020.

2. To consider and approve Director's Report and the annexures thereto of the 28th Annual General Meeting

3. Any other matter with the permission of the Chair.

Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 1st July 2019 and shall re-open 48 hours after the declaration of results.

Outcome of Board meeting held on 15th June, 2020

We wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 15th June ,2020 :

(a) The Audited financial results for the quarter and Year ended 31st March, 2020 along with the Auditor Report thereon (Enclosed herewith) have been adopted by the Board.

Intimation of Board Meeting

We herewith intimate that the meeting of Board of Directors of the Company is scheduled to be held on Monday, 15th June 2020 to transact, inter alia the following:

1. To consider and approve the Audited financial results along with the Auditors Report for the quarter and year ended 31st March 2020.

2.  Any other matter with the permission of the Chair.

Intimation of withdrawal of application by National Company Law Tribunal

In continuation to our earlier intimation about the order passed by the Amaravati Bench of NCLT under the Insolvency and Bankruptcy Code (IBC), we further now wish to inform you that the Company (corporate Debtor) and RR Innovative (Corporate creditor) have settled the matter after payment of entire outstanding amount has been paid. The Settlement Form has been given by Corporate Creditor to the Insolvency Resolution Professional who has filed an application for withdrawal with the Hon’ble NCLT, Amaravati Bench. The Hon’ble NCLT, Amaravati Bench has disposed of as withdrawn the Case No CP(IB) No.172/9/AMR/2019 vide order dated 9th June, 2020 which came to the knowledge of the Company on 11th June, 2020.

Appointment of IRP 

We herewith intimate that the Hon'ble NCLT, Amaravati Bench in the case of RR Innovatives V/s Krebs Biochemicals and Industries Limited vide Case No CP(IB) No.172/9/AMR/2019 passed an Order dated 22nd May, 2020, admitting the case and appointed Shri Rajesh Chhaparia, Insolvency Resolution Professional to carry out the Corporate Insolvency Resolution process of Krebs Biochemicals and Industries Limited.

The order has been passed erroneously not taking into certain facts on record and the accordingly the Company is contesting the matter at the appropriate forum.

Outcome of Board Meeting held on 20th May, 2020

Pursuant to the exercise of conversion option by Ipca Laboratories Ltd. and upon receipt of the balance application money , the Board of directors of  the Company  at their meeting held today   have  allotted 16,20,000 (Sixteen Lakhs Twenty Thousand ) Equity shares of Rs.10/- each  of the Company for cash at a price of Rs. 86/- per Equity Share, including premium of Rs. 76/- per share to M/s Ipca Laboratories Limited, the entity forming part of the promoter group. The Equity shares now allotted on conversion of warrants issued shall rank pari passu with the existing equity shares of the Company in all respects.

The paid up equity capital of the company with the aforesaid allotment has increased from 18000586 equity of Rs. 10/- each to 19620586 Equity shares of Rs.10/- each aggregating to Rs. 19,62,05,860/-

Appointment of Chief Financial Officer and Key Managerial Personnel

The Board of Directors at its meeting held on 30/04/2020 has appointed Mr. Ravi Babu as Chief Financial Officer and Key Managerial Personnel of the Company with effect from 30/04/2020.


2019-20


1st February, 2020

Notice of Board Meeting

This is to inform you that Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to the approval of the members at the EGMs, a meeting of the Board of Directors of the Company will be held on Wednesday, 5th February, 2020 at 12.00 noon to consider allotment of the following equity shares, warrants convertible into equity shares and preference shares of the Company:-

a) 13,70,000 Equity Shares  of Rs. 10 each @ Rs. 86 per share including premium of Rs.76  per share to M/s. Ipca Laboratories Limited, a promoter group shareholder on preferential basis;

b) 35,60,000 warrants convertible into equity shares of the Company @ Rs. 86 per warrant to M/s. Ipca Laboratories Limited, a promoter group shareholder on preferential basis; and

c) 30,00,000, 9%, Redeemable, Non-Convertible, Non-cumulative Preference Shares of  Rs. 100 each to M/s Ipca Laboratories Limited, a promoter group shareholder on preferential basis.

01st February, 2020

Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 1st February,2020 :

The unaudited financial results for the quarter ended 31st December, 2019 along with the Limited Review Report thereon (Enclosed herewith) have been approved by the Board.

24th January, 2020

The meeting of Board of Directors of the Company is scheduled to be held on Saturday, 1st February 2020 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 31st December, 2019.
2.  Any other matter with the permission of the Chair.

Further Issue

Pursuant to the special resolutions passed by the members of the Company at their EGM held on  November 22, 2019, the Company had applied to BSE and NSE for in principle approval for allotment of equity shares and warrants convertible into equity shares to the shareholders forming part of promoter group of the Company on preferential basis in accordance with the terms and conditions of the resolutions passed at the said EGM.

Though one of the exchanges gave its in principle approval to the Company’s application, the other exchange informed the Company that one of the proposed allottee is found to be non-compliant with the provisions of Regulation 160 (c) of SEBI ICDR Regulations since 1000 equity shares held by the allotee is not in demat mode. As per the said allotee 1000 equity shares held in the Company could not be demated since they were deposited in the Court of Law and are a subject matter of an ongoing dispute and therefore, sub judice.

In view of the above, it is proposed to hold a meeting of the Board Directors of the Company on  2nd January, 2020, inter alia, to consider the following:

1. Supersede the resolution No. 2 and 3 passed by the members of the Company at their said EGM held on November 22nd, 2019 for proposed allotment of equity shares and warrants convertible into equity shares on preferential basis; and

2. To consider a fresh, raising of funds needed by the Company through issue of equity shares and warrants convertible into equity shares, on preferential basis, to the compliant member(s).

Disclosure of Related Party Transactions under Regulation 23(9) of SEBI (LODR) Regulations, 2015.

2nd November 2019

Resignation of CFO

We herewith intimate that the Board of Directors has accepted the resignation of Mr. Phani Srinath as Chief Financial Officer of the Company due to his personal reasons and he shall be ceased to be a Chief Financial Officer w.e.f 2nd November, 2019.

Outcome of the Board meeting on 2nd November, 2019

We herewith intimate that the Board of Directors at their meeting held on 2nd November 2019 has considered and approved interalia the following:

1. Unaudited Financial results and Limited Review Report for the quarter and half year ended 30th September, 2019 which are enclosed herewith.

2. The Board has considered and approved the resignation of the Chief Financial Officer of the Company Mr. Phani Srinath.

25th October 2019

Notice of Board Meeting to be held on Saturday, 2nd November 2019

The meeting of Board of Directors of the Company is scheduled to be held on Saturday, 2nd November 2019 to transact, inter alia the following:

1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and half year ended 30th September 2019.

2.  Any other matter with the permission of the Chair.


23rd October 2019

The outcome of the Board meeting

With respect to the issuance of Equity Shares and Warrants convertible into Equity Shares on a preferential basis as well as issue of Preference Shares, we wish to inform you that the board of directors of the Company (the "Board") at its meeting held on October 23, 2019, subject to the approval of the shareholders of the Company, has approved:-

1. To increase the Authorized Share Capital of the Company from the existing Rs. 20,00,00,000 (Rupees Twenty Crore only) divided into 2,00,00,000 (Two Crore) Equity Shares of Rs. 10 each to Rs. 53,00,00,000 (Rupees Fifty Three Crore only), comprising of:

   i. Rs. 23,00,00,000 (Rupees Twenty Three Crore) equity share capital divided into 2,30,00,000 (Two Crore Thirty Lakhs Equity Shares of Rs. 10/- each, and 
   ii. Rs. 30,00,00,000 (Rupees Thirty Crore) preference share capital divided into 30,00,000 (Thirty Lakh Preference Shares) of Rs. 100/- each. 

2. Issue of up to 17,05,000/- (Seventeen  Lakh Five Thousand Only) Equity shares of Rs.10/- each for cash at a price of Rs. 86/- per Equity Share including a premium of Rs. 76/- per share aggregating to Rs. 14,66,30,000/- to the following person/entity who form part of the promoter group (“proposed allottees”) on a preferential basis:

Name of the proposed allottee No. of equity Shares proposed to be allotted
Mrs. Hemalatha Ravi 2,00,000
Ipca Laboratories Limited 15,05,000

3. The issue, on a preferential basis,  of up to 36,35,000 convertible warrants (“Warrant(s)”) of Rs. 86/- each to Ipca Laboratories Limited, a promoter group entity, with a right to the warrant holder to apply for and be allotted, per each warrant,  1  Equity Share of the face value of Rs. 10/- each of the Company (“Equity Shares”) at a price of Rs. 86/- per Equity Share, including a premium of Rs. 76/- per Equity Share, aggregating to Rs. Rs.31,26,10,000/- , within a period of 18 (Eighteen) months from the date of allotment of the Warrants. 

4. The issue, on preferential basis,  up to  30,00,000, 9% Redeemable Non-Convertible Non- Cumulative Preference Shares of Rs. 100/- each aggregating to Rs. 30,00,00,000/- (Rupees Thirty Crores Only)  to Ipca Laboratories Limited. 

5. Please note that an Extraordinary General Meeting of the Company will be held on 22nd November 2019 to obtain shareholder's approval for the above.

The proposed Issue will be undertaken in accordance with the provisions of chapter V of the SEBI ICDR Regulations and any other applicable rules/regulations/ guidelines, if any, prescribed by any other statutory authorities.

October 17, 2019

We wish to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday, October 23, 2019 at 12.00 PM to transact, inter alia the following:

To consider various options to raise funds, including issue, on Preferential basis of Equity shares, Warrants convertible into equity shares and non-cumulative or cumulative redeemable Preference shares subject to approval of the shareholders at the ensuing General meeting, pursuant to applicable provisions of the Companies Act, 2013 along with applicable SEBI (LODR) Regulations, 2015, SEBI (ICDR) Regulations, 2018, as updated from time to time.

Closure of Trading Window

This is to inform you that as per Regulation 9(1) read with Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company’s Code of Conduct to regulate, monitor and report trading by Designated Persons (code of conduct) the trading restriction shall be made applicable from the end of every quarter till 48 hours after the declaration of financial results.

The trading window shall also be applicable to any person having contractual or fiduciary relation with the company, such as auditors, accountancy firms, law firms, analysts, consultants etc., assisting or advising the Company.

All Designated Person(s) of the Company and their immediate relative(s) and other connected person(s) shall conduct all their dealings in the securities of the Company only in a valid Trading Window, and shall not deal in any transaction involving the purchase or sale of the Company’s securities during the periods when Trading Window is closed.

In compliance with the above Regulations and Company’s Code of Conduct, the Trading window for all designated person(s) and their immediate relative(s) shall remain closed with immediate effect and will continue to remain closed till 48 hours after the declaration of the financial results, for the quarter ended September 30, 2019.

Accordingly, the Promoters, Directors, Designated Employees, connected persons and all persons covered under the Code have been advised not to deal in the securities of the Company for the specified period herein.

August 31, 2019

The 27th Annual General Meeting of the members of the company is scheduled to be held on Wednesday, 25th September 2019 at 11:00 AM at Registered office of the Company at Kasimkota (M), Anakapalli, Vishakapatnam(D), Andhra Pradesh – 531031 and in connection to the 27th Annual General Meeting, the Register of Members and Share Transfer Books of the Company shall remain closed from Tuesday, 17th September, 2019 to Wednesday, 25th September, 2019 (both days inclusive).

August 9th, 2019 

Resignation of Ms.Haritha Varanasi, Company Secretary / Compliance Officer 

We wish to intimate that Ms.Haritha Varanasi, Company Secretary / Compliance Officer / Key Managerial Personnel of the Company has been relieved from the services with effect from August 9th, 2019. 

August 9th, 2019 

Ms.Taruni Banda has been appointed as Company Secretary/Compliance officer and Key Managerial Personnel of the Company at the Board of Directors Meeting held on August 9th, 2019 with effect from August 9th, 2019. 

2017-18

2016-17

2015-16

© Krebs Biochemicals and Industries Limited, 2016. All Rights Reserved